drugset / Trial / NCT01474330
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
RandomizedParallel-groupDouble-blindOther
Summary
To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.
Timeline
- Start
- 2011-08-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | 0.5 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 1 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |
Indications
No indication recorded.